Royalty Attributed To OCREVUS — Total Revenue
Biogen Royalty Attributed To OCREVUS — Total Revenue decreased by 17.8% to $317.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.8%, from $288.80M to $317.20M. Over 4 years (FY 2021 to FY 2025), Royalty Attributed To OCREVUS — Total Revenue shows an upward trend with a 9.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and sales performance of the partner-marketed drug, leading to higher royalty income for the company. A decrease suggests slowing sales or potential market share erosion for the underlying product.
Detailed definition
This metric represents the total revenue recognized by the company from royalty payments generated by the sales of OCREV...
Peer comparison
Comparable to royalty revenue streams or profit-sharing arrangements found in pharmaceutical and biotechnology companies with collaborative commercialization agreements.
biib_segment_royalty_attributed_to_ocrevus_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $247.93M | $247.93M | $247.93M | $252.30M | $291.80M | $281.10M | $311.10M | $283.60M | $325.50M | $319.10M | $338.00M | $302.70M | $336.30M | $346.80M | $353.70M | $288.80M | $353.80M | $386.40M | $385.90M | $317.20M |
| QoQ Change | — | +0.0% | +0.0% | +1.8% | +15.7% | -3.7% | +10.7% | -8.8% | +14.8% | -2.0% | +5.9% | -10.4% | +11.1% | +3.1% | +2.0% | -18.3% | +22.5% | +9.2% | -0.1% | -17.8% |
| YoY Change | — | — | — | — | +17.7% | +13.4% | +25.5% | +12.4% | +11.5% | +13.5% | +8.6% | +6.7% | +3.3% | +8.7% | +4.6% | -4.6% | +5.2% | +11.4% | +9.1% | +9.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's royalty attributed to ocrevus — total revenue?
- Biogen (BIIB) reported royalty attributed to ocrevus — total revenue of $317.20M in Q1 2026.
- How has Biogen's royalty attributed to ocrevus — total revenue changed year-over-year?
- Biogen's royalty attributed to ocrevus — total revenue increased by 9.8% year-over-year, from $288.80M to $317.20M.
- What is the long-term trend for Biogen's royalty attributed to ocrevus — total revenue?
- Over 4 years (2021 to 2025), Biogen's royalty attributed to ocrevus — total revenue has grown at a 9.3% compound annual growth rate (CAGR), from $991.70M to $1.41B.
- What does royalty attributed to ocrevus — total revenue mean?
- Total revenue earned from royalty payments based on the sales of the OCREVUS drug.